| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 16 | 2022 | 135 | 4.400 |
Why?
|
| Brain Neoplasms | 22 | 2022 | 228 | 4.130 |
Why?
|
| Hydrocephalus, Normal Pressure | 4 | 2021 | 10 | 2.840 |
Why?
|
| MicroRNAs | 7 | 2019 | 635 | 1.610 |
Why?
|
| Ventriculoperitoneal Shunt | 4 | 2019 | 23 | 1.520 |
Why?
|
| Glioma | 5 | 2017 | 88 | 1.380 |
Why?
|
| Meningioma | 7 | 2014 | 45 | 1.290 |
Why?
|
| Radiosurgery | 4 | 2022 | 51 | 1.200 |
Why?
|
| Meningeal Neoplasms | 6 | 2014 | 46 | 1.190 |
Why?
|
| Wounds, Gunshot | 2 | 2022 | 36 | 1.120 |
Why?
|
| Neoplasm Invasiveness | 6 | 2019 | 201 | 1.000 |
Why?
|
| Neoplastic Stem Cells | 3 | 2015 | 189 | 0.990 |
Why?
|
| Membrane Proteins | 4 | 2021 | 791 | 0.950 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2022 | 15 | 0.910 |
Why?
|
| Humans | 94 | 2022 | 49940 | 0.910 |
Why?
|
| Neurons | 11 | 2004 | 773 | 0.900 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2021 | 4 | 0.890 |
Why?
|
| Neural Cell Adhesion Molecule L1 | 1 | 2021 | 5 | 0.890 |
Why?
|
| Fibrinolysin | 1 | 2021 | 14 | 0.880 |
Why?
|
| Drug Delivery Systems | 2 | 2022 | 274 | 0.870 |
Why?
|
| Hydrocephalus | 1 | 2021 | 25 | 0.870 |
Why?
|
| Cell Proliferation | 3 | 2019 | 879 | 0.850 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 2 | 2014 | 16 | 0.850 |
Why?
|
| Diskectomy | 1 | 2019 | 5 | 0.790 |
Why?
|
| Stuttering | 1 | 2019 | 3 | 0.790 |
Why?
|
| Embolization, Therapeutic | 1 | 2022 | 169 | 0.790 |
Why?
|
| ErbB Receptors | 5 | 2012 | 99 | 0.780 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 39 | 0.770 |
Why?
|
| Spinal Fusion | 1 | 2019 | 43 | 0.760 |
Why?
|
| Animals | 49 | 2022 | 18005 | 0.730 |
Why?
|
| Anesthesia, Obstetrical | 10 | 1993 | 26 | 0.700 |
Why?
|
| Cell Movement | 5 | 2013 | 393 | 0.690 |
Why?
|
| Serotonin | 7 | 2018 | 68 | 0.660 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 527 | 0.660 |
Why?
|
| Proteomics | 5 | 2005 | 201 | 0.630 |
Why?
|
| Dual-Specificity Phosphatases | 2 | 2014 | 7 | 0.610 |
Why?
|
| Mice | 29 | 2021 | 9199 | 0.610 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2016 | 16 | 0.600 |
Why?
|
| Cell Line, Tumor | 7 | 2019 | 1240 | 0.600 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2015 | 2 | 0.590 |
Why?
|
| Craniotomy | 1 | 2015 | 13 | 0.580 |
Why?
|
| Cerebrum | 1 | 2015 | 13 | 0.580 |
Why?
|
| Wakefulness | 1 | 2015 | 43 | 0.560 |
Why?
|
| Ribosome Subunits, Small, Eukaryotic | 1 | 2014 | 3 | 0.560 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 2014 | 6 | 0.560 |
Why?
|
| rho-Associated Kinases | 1 | 2014 | 10 | 0.530 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2014 | 18 | 0.530 |
Why?
|
| Male | 33 | 2022 | 23385 | 0.510 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2015 | 289 | 0.510 |
Why?
|
| Alcoholism | 1 | 2016 | 263 | 0.500 |
Why?
|
| Protein Biosynthesis | 3 | 2014 | 296 | 0.500 |
Why?
|
| Alternative Splicing | 2 | 2012 | 120 | 0.490 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2012 | 9 | 0.470 |
Why?
|
| DNA Damage | 4 | 2004 | 281 | 0.470 |
Why?
|
| Apoptosis | 8 | 2010 | 1009 | 0.460 |
Why?
|
| Multigene Family | 2 | 2010 | 95 | 0.460 |
Why?
|
| Anesthesia, Epidural | 6 | 1993 | 24 | 0.460 |
Why?
|
| Female | 51 | 2022 | 26574 | 0.460 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2012 | 6 | 0.460 |
Why?
|
| DNA Copy Number Variations | 4 | 2019 | 60 | 0.460 |
Why?
|
| Chromosomal Instability | 1 | 2012 | 22 | 0.450 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2021 | 1375 | 0.450 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2010 | 47 | 0.440 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2004 | 299 | 0.440 |
Why?
|
| Salvage Therapy | 3 | 2017 | 47 | 0.440 |
Why?
|
| Blood-Brain Barrier | 2 | 2022 | 68 | 0.440 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2019 | 78 | 0.430 |
Why?
|
| Neoplasms | 3 | 2014 | 1014 | 0.420 |
Why?
|
| Aged | 20 | 2020 | 10953 | 0.410 |
Why?
|
| Mice, Nude | 11 | 2013 | 220 | 0.410 |
Why?
|
| Blotting, Western | 7 | 2012 | 565 | 0.400 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 767 | 0.380 |
Why?
|
| Genomic Imprinting | 1 | 2010 | 52 | 0.380 |
Why?
|
| RNA, Messenger | 11 | 2011 | 1432 | 0.380 |
Why?
|
| Oncogenes | 1 | 2010 | 61 | 0.380 |
Why?
|
| Wnt Proteins | 1 | 2010 | 91 | 0.380 |
Why?
|
| Brain | 5 | 2022 | 1179 | 0.380 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 398 | 0.380 |
Why?
|
| Travel-Related Illness | 2 | 2019 | 2 | 0.370 |
Why?
|
| Transcription Factors | 3 | 2010 | 1402 | 0.370 |
Why?
|
| Laryngoscopy | 2 | 2008 | 28 | 0.370 |
Why?
|
| Anti-Bacterial Agents | 3 | 2019 | 602 | 0.360 |
Why?
|
| Adult | 30 | 2020 | 13401 | 0.360 |
Why?
|
| Synapses | 4 | 1995 | 144 | 0.360 |
Why?
|
| Gene Deletion | 3 | 2021 | 301 | 0.360 |
Why?
|
| Immunohistochemistry | 10 | 2012 | 817 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2019 | 453 | 0.350 |
Why?
|
| Hypopharynx | 1 | 2008 | 3 | 0.350 |
Why?
|
| Caspases | 3 | 2002 | 156 | 0.350 |
Why?
|
| Clindamycin | 1 | 2008 | 11 | 0.350 |
Why?
|
| Osteonecrosis | 1 | 2008 | 5 | 0.350 |
Why?
|
| Pharyngeal Diseases | 1 | 2008 | 8 | 0.350 |
Why?
|
| Glycoproteins | 4 | 2012 | 187 | 0.340 |
Why?
|
| Capsules | 1 | 2008 | 30 | 0.340 |
Why?
|
| Treatment Outcome | 9 | 2022 | 3901 | 0.340 |
Why?
|
| HIV | 1 | 2008 | 75 | 0.340 |
Why?
|
| Middle Aged | 24 | 2020 | 13559 | 0.330 |
Why?
|
| Intracranial Arteriosclerosis | 3 | 2013 | 31 | 0.330 |
Why?
|
| Travel | 2 | 2019 | 27 | 0.320 |
Why?
|
| MAP Kinase Signaling System | 3 | 2010 | 195 | 0.320 |
Why?
|
| Receptor, EphA2 | 1 | 2006 | 2 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2004 | 91 | 0.310 |
Why?
|
| Signal Transduction | 6 | 2015 | 2736 | 0.310 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2007 | 58 | 0.310 |
Why?
|
| Gene Dosage | 3 | 2011 | 60 | 0.310 |
Why?
|
| Anesthesia, Spinal | 4 | 1991 | 22 | 0.310 |
Why?
|
| Genome, Human | 3 | 2011 | 207 | 0.310 |
Why?
|
| Retrospective Studies | 8 | 2022 | 4530 | 0.300 |
Why?
|
| Gene Expression Profiling | 7 | 2015 | 691 | 0.300 |
Why?
|
| Genes, p53 | 3 | 2004 | 49 | 0.290 |
Why?
|
| Protein Binding | 3 | 2021 | 1502 | 0.290 |
Why?
|
| Stents | 3 | 2013 | 338 | 0.280 |
Why?
|
| Transfection | 7 | 2010 | 643 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2017 | 243 | 0.280 |
Why?
|
| Down-Regulation | 3 | 2021 | 283 | 0.280 |
Why?
|
| Pain, Intractable | 1 | 2004 | 6 | 0.270 |
Why?
|
| Trigeminal Neuralgia | 1 | 2004 | 7 | 0.270 |
Why?
|
| Neoplasm Transplantation | 8 | 2013 | 148 | 0.270 |
Why?
|
| Neurosurgical Procedures | 1 | 2004 | 32 | 0.270 |
Why?
|
| Electric Stimulation Therapy | 1 | 2004 | 23 | 0.270 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 4244 | 0.260 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2006 | 198 | 0.260 |
Why?
|
| Neurodegenerative Diseases | 2 | 2005 | 92 | 0.260 |
Why?
|
| Mammary Neoplasms, Experimental | 5 | 2008 | 60 | 0.250 |
Why?
|
| RNA Interference | 3 | 2014 | 581 | 0.250 |
Why?
|
| Hippocampus | 2 | 1998 | 184 | 0.250 |
Why?
|
| Mass Spectrometry | 2 | 2004 | 262 | 0.250 |
Why?
|
| Cesarean Section | 9 | 1991 | 75 | 0.250 |
Why?
|
| Parkinson Disease | 2 | 2019 | 80 | 0.250 |
Why?
|
| Angioplasty | 2 | 2013 | 41 | 0.240 |
Why?
|
| Rats | 11 | 2014 | 1819 | 0.230 |
Why?
|
| Didanosine | 1 | 2002 | 3 | 0.230 |
Why?
|
| Retinoblastoma Protein | 2 | 2014 | 36 | 0.230 |
Why?
|
| Glasgow Coma Scale | 1 | 2022 | 29 | 0.230 |
Why?
|
| Tumor Cells, Cultured | 10 | 2012 | 445 | 0.230 |
Why?
|
| Neovascularization, Pathologic | 3 | 2010 | 118 | 0.230 |
Why?
|
| Bupivacaine | 3 | 1993 | 30 | 0.230 |
Why?
|
| Adenosine Deaminase | 1 | 2002 | 11 | 0.230 |
Why?
|
| Injury Severity Score | 1 | 2022 | 76 | 0.230 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 521 | 0.220 |
Why?
|
| Microsurgery | 1 | 2022 | 45 | 0.220 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2019 | 28 | 0.220 |
Why?
|
| Neoplasm Grading | 4 | 2017 | 71 | 0.220 |
Why?
|
| Prodrugs | 1 | 2002 | 29 | 0.220 |
Why?
|
| Gene Expression Regulation | 4 | 2021 | 1517 | 0.220 |
Why?
|
| Phenotype | 4 | 2015 | 1004 | 0.220 |
Why?
|
| Geologic Sediments | 1 | 2001 | 3 | 0.220 |
Why?
|
| Cell Division | 8 | 2010 | 427 | 0.220 |
Why?
|
| Enzyme Activation | 3 | 2014 | 343 | 0.220 |
Why?
|
| Soil Pollutants | 1 | 2001 | 18 | 0.210 |
Why?
|
| Soil | 1 | 2001 | 19 | 0.210 |
Why?
|
| Raphe Nuclei | 3 | 1995 | 5 | 0.210 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2001 | 19 | 0.210 |
Why?
|
| Protein Kinases | 1 | 2002 | 136 | 0.210 |
Why?
|
| Water Pollutants, Chemical | 1 | 2001 | 23 | 0.210 |
Why?
|
| CDC2 Protein Kinase | 2 | 2014 | 32 | 0.210 |
Why?
|
| Proteins | 5 | 2002 | 707 | 0.210 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 1951 | 0.210 |
Why?
|
| Cell Adhesion | 3 | 2019 | 218 | 0.210 |
Why?
|
| Basal Ganglia Hemorrhage | 1 | 2020 | 2 | 0.210 |
Why?
|
| HIV Infections | 1 | 2008 | 897 | 0.210 |
Why?
|
| Protein Domains | 1 | 2021 | 126 | 0.210 |
Why?
|
| Isotonic Solutions | 2 | 1991 | 17 | 0.210 |
Why?
|
| Lung Neoplasms | 4 | 2013 | 432 | 0.200 |
Why?
|
| Central Nervous System | 1 | 2002 | 138 | 0.200 |
Why?
|
| Cells, Cultured | 9 | 2002 | 2067 | 0.200 |
Why?
|
| Chemical Hazard Release | 1 | 2020 | 1 | 0.200 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2014 | 55 | 0.200 |
Why?
|
| Catheter Obstruction | 1 | 2019 | 2 | 0.200 |
Why?
|
| Ammonia | 1 | 2020 | 14 | 0.200 |
Why?
|
| Vocal Cord Paralysis | 1 | 2019 | 6 | 0.200 |
Why?
|
| Hodgkin Disease | 1 | 2000 | 53 | 0.200 |
Why?
|
| Breast Neoplasms | 6 | 2019 | 1020 | 0.200 |
Why?
|
| Spinal Puncture | 1 | 2019 | 14 | 0.190 |
Why?
|
| HeLa Cells | 1 | 2021 | 518 | 0.190 |
Why?
|
| Thalamus | 1 | 2000 | 46 | 0.190 |
Why?
|
| Promoter Regions, Genetic | 3 | 2015 | 643 | 0.190 |
Why?
|
| Memory, Short-Term | 1 | 2000 | 52 | 0.190 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 8 | 0.190 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 19 | 0.190 |
Why?
|
| Nanotubes, Carbon | 1 | 2019 | 15 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 188 | 0.190 |
Why?
|
| Drainage | 1 | 2019 | 107 | 0.190 |
Why?
|
| Oncogene Protein v-akt | 1 | 2019 | 15 | 0.190 |
Why?
|
| Pregnancy | 12 | 1993 | 2091 | 0.190 |
Why?
|
| Diagnosis, Differential | 3 | 2008 | 752 | 0.190 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 87 | 0.180 |
Why?
|
| Reoperation | 1 | 2019 | 177 | 0.180 |
Why?
|
| History, 21st Century | 1 | 2019 | 137 | 0.180 |
Why?
|
| Lipids | 1 | 2021 | 292 | 0.180 |
Why?
|
| Language | 1 | 2000 | 115 | 0.180 |
Why?
|
| Diarrhea | 2 | 2019 | 66 | 0.180 |
Why?
|
| Dacarbazine | 2 | 2015 | 18 | 0.180 |
Why?
|
| Melatonin | 1 | 2018 | 69 | 0.180 |
Why?
|
| History, 20th Century | 1 | 2019 | 219 | 0.180 |
Why?
|
| Genomics | 2 | 2012 | 271 | 0.180 |
Why?
|
| Cellular Senescence | 1 | 1999 | 90 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 158 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2015 | 25 | 0.180 |
Why?
|
| Military Personnel | 1 | 2019 | 73 | 0.180 |
Why?
|
| Betacoronavirus | 1 | 2020 | 148 | 0.180 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 69 | 0.170 |
Why?
|
| Neuroprotective Agents | 1 | 2018 | 57 | 0.170 |
Why?
|
| Environmental Exposure | 1 | 2020 | 188 | 0.170 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2006 | 99 | 0.170 |
Why?
|
| Re-Irradiation | 1 | 2017 | 2 | 0.170 |
Why?
|
| RNA | 1 | 2021 | 368 | 0.170 |
Why?
|
| Thiophenes | 2 | 2014 | 37 | 0.170 |
Why?
|
| Bevacizumab | 1 | 2017 | 35 | 0.170 |
Why?
|
| Phosphorylation | 3 | 2015 | 809 | 0.160 |
Why?
|
| Osteoporosis | 1 | 2018 | 134 | 0.160 |
Why?
|
| Time Factors | 6 | 2017 | 3184 | 0.160 |
Why?
|
| Wounds and Injuries | 1 | 2020 | 211 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2018 | 118 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 170 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 183 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 36 | 0.160 |
Why?
|
| Cell Growth Processes | 2 | 2007 | 35 | 0.160 |
Why?
|
| Sequence Analysis, DNA | 3 | 2011 | 375 | 0.160 |
Why?
|
| Brain Injuries | 1 | 2018 | 127 | 0.160 |
Why?
|
| Pregnancy Complications | 2 | 1993 | 383 | 0.150 |
Why?
|
| In Vitro Techniques | 4 | 2012 | 452 | 0.150 |
Why?
|
| Base Sequence | 3 | 2010 | 1306 | 0.150 |
Why?
|
| Analgesia, Epidural | 3 | 1990 | 27 | 0.150 |
Why?
|
| Influenza, Human | 1 | 2018 | 193 | 0.150 |
Why?
|
| Sleep | 1 | 2018 | 192 | 0.150 |
Why?
|
| Stroke | 3 | 2013 | 891 | 0.150 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2015 | 3 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2008 | 287 | 0.140 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 20 | 0.140 |
Why?
|
| Cell Death | 3 | 2002 | 247 | 0.140 |
Why?
|
| Disease Progression | 3 | 2017 | 720 | 0.140 |
Why?
|
| Mutation | 3 | 2015 | 2246 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 34 | 0.140 |
Why?
|
| Constriction, Pathologic | 2 | 2012 | 60 | 0.140 |
Why?
|
| Peptides | 2 | 2012 | 512 | 0.140 |
Why?
|
| Self Administration | 1 | 2014 | 41 | 0.140 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2014 | 11 | 0.140 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 52 | 0.140 |
Why?
|
| Mice, Transgenic | 6 | 2008 | 1124 | 0.140 |
Why?
|
| Ischemic Attack, Transient | 2 | 2013 | 77 | 0.130 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2013 | 209 | 0.130 |
Why?
|
| Brain Mapping | 1 | 2015 | 180 | 0.130 |
Why?
|
| E2F Transcription Factors | 1 | 2014 | 16 | 0.130 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2014 | 16 | 0.130 |
Why?
|
| Tumor Burden | 2 | 2013 | 58 | 0.130 |
Why?
|
| Actomyosin | 1 | 2014 | 19 | 0.130 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2014 | 24 | 0.130 |
Why?
|
| Glucosides | 1 | 2014 | 10 | 0.130 |
Why?
|
| Animals, Newborn | 5 | 1996 | 237 | 0.130 |
Why?
|
| Protein Subunits | 1 | 2014 | 147 | 0.130 |
Why?
|
| Glutamates | 1 | 1994 | 14 | 0.130 |
Why?
|
| Exosomes | 1 | 2014 | 37 | 0.130 |
Why?
|
| Combined Modality Therapy | 4 | 2014 | 301 | 0.130 |
Why?
|
| Type C Phospholipases | 1 | 1994 | 35 | 0.130 |
Why?
|
| Tumor Microenvironment | 1 | 2014 | 110 | 0.130 |
Why?
|
| Cell Nucleolus | 1 | 2014 | 66 | 0.130 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2014 | 43 | 0.130 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2014 | 66 | 0.130 |
Why?
|
| NADPH Dehydrogenase | 1 | 1993 | 4 | 0.130 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 1990 | 24 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2019 | 905 | 0.130 |
Why?
|
| Catecholamines | 1 | 1993 | 27 | 0.120 |
Why?
|
| Adolescent | 6 | 2020 | 5397 | 0.120 |
Why?
|
| Cytoplasm | 1 | 2014 | 254 | 0.120 |
Why?
|
| Marfan Syndrome | 1 | 1993 | 10 | 0.120 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 293 | 0.120 |
Why?
|
| Serine Endopeptidases | 1 | 2013 | 80 | 0.120 |
Why?
|
| bcl-2-Associated X Protein | 3 | 2004 | 40 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2008 | 91 | 0.120 |
Why?
|
| Risk Factors | 5 | 2018 | 4294 | 0.120 |
Why?
|
| Electrophysiology | 3 | 2000 | 66 | 0.120 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 852 | 0.120 |
Why?
|
| Perioperative Period | 1 | 2012 | 16 | 0.120 |
Why?
|
| AC133 Antigen | 1 | 2012 | 4 | 0.120 |
Why?
|
| Young Adult | 6 | 2020 | 3699 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 58 | 0.120 |
Why?
|
| Transplantation, Heterologous | 4 | 2010 | 219 | 0.120 |
Why?
|
| Pain, Postoperative | 3 | 1990 | 105 | 0.120 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 113 | 0.110 |
Why?
|
| Glucose | 1 | 2015 | 383 | 0.110 |
Why?
|
| Patient Compliance | 1 | 2014 | 344 | 0.110 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2012 | 27 | 0.110 |
Why?
|
| Genes, myc | 3 | 2004 | 20 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 189 | 0.110 |
Why?
|
| Antigens, CD | 2 | 2012 | 306 | 0.110 |
Why?
|
| Astrocytoma | 2 | 2009 | 9 | 0.110 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2011 | 2 | 0.110 |
Why?
|
| Ephedrine | 1 | 1991 | 3 | 0.110 |
Why?
|
| DNA Modification Methylases | 1 | 2011 | 13 | 0.110 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1991 | 7 | 0.110 |
Why?
|
| Prospective Studies | 6 | 2019 | 2559 | 0.110 |
Why?
|
| DNA Repair Enzymes | 1 | 2011 | 32 | 0.110 |
Why?
|
| Fetal Blood | 1 | 1991 | 75 | 0.100 |
Why?
|
| Hospitalization | 2 | 2015 | 1093 | 0.100 |
Why?
|
| Meperidine | 1 | 1990 | 4 | 0.100 |
Why?
|
| DNA Primers | 2 | 2010 | 292 | 0.100 |
Why?
|
| Snail Family Transcription Factors | 1 | 2010 | 25 | 0.100 |
Why?
|
| Scoliosis | 1 | 1990 | 8 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 4 | 2002 | 2915 | 0.100 |
Why?
|
| Fentanyl | 4 | 1993 | 51 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2009 | 168 | 0.100 |
Why?
|
| Adenoviridae | 2 | 2002 | 113 | 0.100 |
Why?
|
| Epidermal Growth Factor | 1 | 2010 | 54 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2010 | 8 | 0.100 |
Why?
|
| Shivering | 1 | 1990 | 1 | 0.100 |
Why?
|
| Databases, Nucleic Acid | 1 | 2010 | 7 | 0.100 |
Why?
|
| Ganglia, Sympathetic | 1 | 1989 | 5 | 0.100 |
Why?
|
| Obstetric Labor Complications | 1 | 1990 | 22 | 0.100 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 805 | 0.100 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 75 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2012 | 654 | 0.100 |
Why?
|
| Myotonic Dystrophy | 1 | 1990 | 9 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2010 | 14 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 339 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2013 | 652 | 0.100 |
Why?
|
| Cell Survival | 2 | 2002 | 538 | 0.100 |
Why?
|
| Immunoblotting | 2 | 2004 | 185 | 0.100 |
Why?
|
| Abdomen | 1 | 1990 | 94 | 0.100 |
Why?
|
| beta Catenin | 1 | 2010 | 81 | 0.100 |
Why?
|
| GTP-Binding Proteins | 1 | 2010 | 78 | 0.100 |
Why?
|
| Intracranial Arterial Diseases | 1 | 2009 | 3 | 0.100 |
Why?
|
| Fetal Organ Maturity | 1 | 1989 | 3 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 184 | 0.100 |
Why?
|
| GTPase-Activating Proteins | 1 | 2010 | 61 | 0.090 |
Why?
|
| Infant | 3 | 2020 | 1382 | 0.090 |
Why?
|
| Comparative Genomic Hybridization | 3 | 2015 | 18 | 0.090 |
Why?
|
| Proto-Oncogenes | 1 | 1989 | 9 | 0.090 |
Why?
|
| Growth Substances | 1 | 1989 | 36 | 0.090 |
Why?
|
| Urethral Obstruction | 1 | 1989 | 4 | 0.090 |
Why?
|
| Fetal Diseases | 1 | 1989 | 20 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 373 | 0.090 |
Why?
|
| Anesthesia, General | 1 | 1989 | 36 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2020 | 1725 | 0.090 |
Why?
|
| Calcinosis | 1 | 2009 | 69 | 0.090 |
Why?
|
| Tenascin | 1 | 2008 | 2 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 1989 | 119 | 0.090 |
Why?
|
| Fetus | 1 | 1989 | 101 | 0.090 |
Why?
|
| Rats, Inbred Strains | 4 | 1995 | 157 | 0.090 |
Why?
|
| Biomarkers, Tumor | 2 | 2009 | 422 | 0.090 |
Why?
|
| Neoplasm Metastasis | 4 | 2019 | 200 | 0.090 |
Why?
|
| Cell Line | 2 | 2012 | 1965 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 1063 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 284 | 0.090 |
Why?
|
| Age Factors | 3 | 2018 | 1424 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 1989 | 95 | 0.080 |
Why?
|
| Cattle | 2 | 2002 | 300 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2010 | 247 | 0.080 |
Why?
|
| Blotting, Northern | 4 | 2008 | 146 | 0.080 |
Why?
|
| Endothelium, Vascular | 2 | 2002 | 160 | 0.080 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2008 | 58 | 0.080 |
Why?
|
| Respiration | 1 | 1988 | 78 | 0.080 |
Why?
|
| Intubation, Intratracheal | 1 | 1988 | 89 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2014 | 255 | 0.080 |
Why?
|
| Zebrafish | 1 | 2010 | 296 | 0.080 |
Why?
|
| Pandemics | 2 | 2022 | 424 | 0.080 |
Why?
|
| Radiography | 1 | 2008 | 342 | 0.080 |
Why?
|
| Myocardial Infarction | 2 | 1990 | 846 | 0.080 |
Why?
|
| Isoenzymes | 1 | 2007 | 132 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 3 | 2008 | 102 | 0.080 |
Why?
|
| Proteome | 2 | 2004 | 103 | 0.080 |
Why?
|
| Anti-HIV Agents | 1 | 2008 | 172 | 0.080 |
Why?
|
| Propensity Score | 2 | 2017 | 116 | 0.070 |
Why?
|
| Intensive Care Units | 1 | 1989 | 334 | 0.070 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2010 | 602 | 0.070 |
Why?
|
| Gene Amplification | 1 | 2005 | 22 | 0.070 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2015 | 13 | 0.070 |
Why?
|
| Lung | 1 | 1989 | 612 | 0.070 |
Why?
|
| Trauma, Nervous System | 1 | 2005 | 2 | 0.070 |
Why?
|
| Tyrosine 3-Monooxygenase | 3 | 1994 | 32 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 1989 | 350 | 0.070 |
Why?
|
| Motor Neuron Disease | 1 | 2005 | 25 | 0.070 |
Why?
|
| Prognosis | 3 | 2014 | 1257 | 0.070 |
Why?
|
| Glutamine | 1 | 2005 | 34 | 0.070 |
Why?
|
| Child | 3 | 2020 | 3828 | 0.070 |
Why?
|
| Algorithms | 2 | 2011 | 893 | 0.070 |
Why?
|
| Trigeminal Nerve Injuries | 1 | 2004 | 1 | 0.070 |
Why?
|
| Electrodes, Implanted | 1 | 2004 | 18 | 0.070 |
Why?
|
| tau Proteins | 1 | 2005 | 79 | 0.070 |
Why?
|
| Phalloidine | 1 | 2004 | 4 | 0.070 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2004 | 30 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 1954 | 0.070 |
Why?
|
| Free Radicals | 1 | 2004 | 15 | 0.070 |
Why?
|
| Herpes Zoster | 1 | 2004 | 22 | 0.070 |
Why?
|
| Sex Factors | 2 | 2018 | 856 | 0.070 |
Why?
|
| Receptors, Virus | 1 | 2004 | 80 | 0.070 |
Why?
|
| Chromosome Mapping | 1 | 2005 | 291 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 634 | 0.070 |
Why?
|
| Feces | 2 | 2014 | 88 | 0.070 |
Why?
|
| Down Syndrome | 1 | 2005 | 43 | 0.070 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 1994 | 66 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2004 | 163 | 0.060 |
Why?
|
| Coloring Agents | 1 | 2004 | 50 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 75 | 0.060 |
Why?
|
| Pain Measurement | 1 | 2004 | 253 | 0.060 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2002 | 14 | 0.060 |
Why?
|
| Oxygen | 1 | 2004 | 246 | 0.060 |
Why?
|
| Camptothecin | 1 | 2002 | 21 | 0.060 |
Why?
|
| Neurosciences | 1 | 2002 | 25 | 0.060 |
Why?
|
| Ticlopidine | 2 | 2013 | 58 | 0.060 |
Why?
|
| Survival Rate | 2 | 2014 | 666 | 0.060 |
Why?
|
| Nervous System | 1 | 2002 | 69 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 80 | 0.060 |
Why?
|
| Injections, Epidural | 3 | 1990 | 4 | 0.060 |
Why?
|
| Neurology | 1 | 2001 | 23 | 0.060 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2001 | 20 | 0.050 |
Why?
|
| Labor, Obstetric | 2 | 1992 | 26 | 0.050 |
Why?
|
| Anesthesia, Intravenous | 2 | 1993 | 14 | 0.050 |
Why?
|
| Environmental Pollution | 1 | 2001 | 9 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2298 | 0.050 |
Why?
|
| Trauma Centers | 1 | 2022 | 74 | 0.050 |
Why?
|
| Humic Substances | 1 | 2001 | 3 | 0.050 |
Why?
|
| S Phase | 1 | 2001 | 75 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2004 | 754 | 0.050 |
Why?
|
| DNA Restriction Enzymes | 1 | 2001 | 35 | 0.050 |
Why?
|
| Calorimetry | 1 | 2001 | 37 | 0.050 |
Why?
|
| Aspirin | 2 | 2013 | 173 | 0.050 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2001 | 44 | 0.050 |
Why?
|
| Adsorption | 1 | 2001 | 76 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2002 | 353 | 0.050 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2000 | 13 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2012 | 241 | 0.050 |
Why?
|
| Incidence | 2 | 2015 | 1132 | 0.050 |
Why?
|
| Protein Transport | 1 | 2002 | 391 | 0.050 |
Why?
|
| Injections, Spinal | 2 | 2011 | 38 | 0.050 |
Why?
|
| Models, Chemical | 1 | 2001 | 132 | 0.050 |
Why?
|
| Transduction, Genetic | 1 | 2002 | 210 | 0.050 |
Why?
|
| Illinois | 1 | 2020 | 12 | 0.050 |
Why?
|
| Mathematics | 1 | 2000 | 28 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2005 | 399 | 0.050 |
Why?
|
| Anesthetics, Local | 2 | 1990 | 50 | 0.050 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 53 | 0.050 |
Why?
|
| Genome | 3 | 2011 | 224 | 0.050 |
Why?
|
| Metalloendopeptidases | 2 | 1996 | 23 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2019 | 346 | 0.050 |
Why?
|
| Antidiarrheals | 1 | 2019 | 1 | 0.050 |
Why?
|
| Medical Records | 1 | 2020 | 135 | 0.050 |
Why?
|
| DNA Replication | 1 | 2001 | 222 | 0.050 |
Why?
|
| Travel Medicine | 1 | 2019 | 3 | 0.050 |
Why?
|
| Hepatitis A | 1 | 2019 | 11 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 1999 | 32 | 0.050 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1998 | 6 | 0.050 |
Why?
|
| Staurosporine | 1 | 1998 | 11 | 0.050 |
Why?
|
| Receptor, Melatonin, MT2 | 1 | 2018 | 3 | 0.050 |
Why?
|
| Receptor, Melatonin, MT1 | 1 | 2018 | 5 | 0.050 |
Why?
|
| Receptors, Melatonin | 1 | 2018 | 33 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2002 | 289 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 71 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 1998 | 173 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 38 | 0.040 |
Why?
|
| Malaria | 1 | 2019 | 85 | 0.040 |
Why?
|
| Surface Properties | 1 | 2019 | 251 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 2 | 1995 | 6 | 0.040 |
Why?
|
| Regeneration | 1 | 2018 | 94 | 0.040 |
Why?
|
| Virus Diseases | 1 | 2018 | 114 | 0.040 |
Why?
|
| Vaccination | 1 | 2019 | 260 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2018 | 257 | 0.040 |
Why?
|
| Ascites | 1 | 1996 | 20 | 0.040 |
Why?
|
| Phenylalanine | 1 | 1996 | 26 | 0.040 |
Why?
|
| Models, Biological | 1 | 2002 | 1123 | 0.040 |
Why?
|
| Self Report | 1 | 2018 | 322 | 0.040 |
Why?
|
| Models, Genetic | 2 | 2011 | 254 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2014 | 2094 | 0.040 |
Why?
|
| Receptor, Insulin | 1 | 1996 | 45 | 0.040 |
Why?
|
| Infusion Pumps | 2 | 1992 | 6 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2015 | 6 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2015 | 9 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 1996 | 101 | 0.040 |
Why?
|
| Selection Bias | 1 | 2015 | 23 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 2015 | 105 | 0.040 |
Why?
|
| 5,7-Dihydroxytryptamine | 1 | 1994 | 3 | 0.040 |
Why?
|
| Microelectrodes | 1 | 1994 | 12 | 0.030 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1994 | 15 | 0.030 |
Why?
|
| Serotonin Receptor Agonists | 1 | 1994 | 10 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1995 | 63 | 0.030 |
Why?
|
| Neurites | 1 | 1994 | 23 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 1994 | 660 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1995 | 226 | 0.030 |
Why?
|
| Axons | 1 | 1995 | 115 | 0.030 |
Why?
|
| Ion Channel Gating | 1 | 1994 | 37 | 0.030 |
Why?
|
| Glycerides | 1 | 1994 | 2 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 1994 | 104 | 0.030 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 1994 | 4 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1994 | 16 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 1994 | 48 | 0.030 |
Why?
|
| Canagliflozin | 1 | 2014 | 2 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 2014 | 9 | 0.030 |
Why?
|
| Glucuronides | 1 | 2014 | 6 | 0.030 |
Why?
|
| Bile | 1 | 2014 | 14 | 0.030 |
Why?
|
| Meninges | 1 | 1994 | 6 | 0.030 |
Why?
|
| Cell Communication | 1 | 1994 | 120 | 0.030 |
Why?
|
| Nitroglycerin | 2 | 1990 | 11 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 152 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 57 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 1994 | 71 | 0.030 |
Why?
|
| Tyrosine | 1 | 1994 | 80 | 0.030 |
Why?
|
| Heart Rate, Fetal | 1 | 1993 | 2 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2013 | 110 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 236 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 1993 | 43 | 0.030 |
Why?
|
| Metoclopramide | 1 | 1993 | 7 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 327 | 0.030 |
Why?
|
| Nucleoside-Diphosphate Kinase | 1 | 1993 | 2 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1993 | 145 | 0.030 |
Why?
|
| Labor, Induced | 1 | 1993 | 26 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 600 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 126 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 300 | 0.030 |
Why?
|
| Antibodies | 1 | 1993 | 161 | 0.030 |
Why?
|
| Fibroblast Growth Factors | 1 | 1993 | 57 | 0.030 |
Why?
|
| Dogs | 1 | 2014 | 286 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 1993 | 149 | 0.030 |
Why?
|
| Neuronal Plasticity | 1 | 1994 | 110 | 0.030 |
Why?
|
| Foreign-Body Migration | 1 | 1992 | 13 | 0.030 |
Why?
|
| Carotid Stenosis | 1 | 2013 | 85 | 0.030 |
Why?
|
| Cardiac Catheterization | 2 | 1990 | 162 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 515 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2012 | 91 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2013 | 112 | 0.030 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 1993 | 36 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2012 | 53 | 0.030 |
Why?
|
| Adipocytes | 1 | 1994 | 222 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 1993 | 220 | 0.030 |
Why?
|
| Neoplasms, Experimental | 2 | 1989 | 67 | 0.030 |
Why?
|
| Catheters, Indwelling | 1 | 1992 | 62 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 118 | 0.030 |
Why?
|
| Heart Rate | 1 | 1993 | 265 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1993 | 269 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1993 | 254 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 1994 | 1249 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2011 | 90 | 0.030 |
Why?
|
| Intracranial Hemorrhages | 1 | 2011 | 38 | 0.030 |
Why?
|
| Gelatinases | 3 | 1996 | 9 | 0.030 |
Why?
|
| Umbilical Veins | 1 | 1991 | 16 | 0.030 |
Why?
|
| Umbilical Arteries | 1 | 1991 | 7 | 0.030 |
Why?
|
| Logistic Models | 1 | 2014 | 1168 | 0.030 |
Why?
|
| Procaine | 1 | 1990 | 2 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 176 | 0.030 |
Why?
|
| Recurrence | 1 | 2012 | 500 | 0.030 |
Why?
|
| Receptors, Opioid | 1 | 1990 | 12 | 0.030 |
Why?
|
| Analgesia, Obstetrical | 1 | 1990 | 18 | 0.030 |
Why?
|
| Alfentanil | 1 | 1990 | 4 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 855 | 0.030 |
Why?
|
| Anesthesia Recovery Period | 1 | 1990 | 6 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 1991 | 144 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 358 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 57 | 0.020 |
Why?
|
| Prostaglandin D2 | 1 | 1990 | 5 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 154 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1990 | 102 | 0.020 |
Why?
|
| Nerve Block | 1 | 1990 | 28 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 299 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 1990 | 60 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1991 | 461 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 25 | 0.020 |
Why?
|
| Annexins | 1 | 1989 | 7 | 0.020 |
Why?
|
| Embolism, Air | 1 | 1989 | 9 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1989 | 46 | 0.020 |
Why?
|
| DNA Probes | 1 | 1989 | 34 | 0.020 |
Why?
|
| Cerebral Ventricles | 1 | 1989 | 28 | 0.020 |
Why?
|
| Oximetry | 1 | 1989 | 39 | 0.020 |
Why?
|
| Succinylcholine | 1 | 1989 | 6 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 1989 | 36 | 0.020 |
Why?
|
| Isoflurane | 1 | 1989 | 14 | 0.020 |
Why?
|
| Appendicitis | 1 | 1990 | 68 | 0.020 |
Why?
|
| Epithelium | 1 | 1989 | 101 | 0.020 |
Why?
|
| Anesthesia, Inhalation | 1 | 1989 | 12 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 421 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2009 | 79 | 0.020 |
Why?
|
| Sheep | 1 | 1989 | 149 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 1989 | 101 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1991 | 757 | 0.020 |
Why?
|
| Gestational Age | 1 | 1989 | 173 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2008 | 14 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 910 | 0.020 |
Why?
|
| Gene Expression | 3 | 1998 | 773 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2009 | 135 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 1990 | 202 | 0.020 |
Why?
|
| Health Behavior | 1 | 2011 | 462 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1990 | 502 | 0.020 |
Why?
|
| Neutrophils | 1 | 1990 | 339 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 831 | 0.020 |
Why?
|
| Calcium | 1 | 1990 | 521 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2004 | 1899 | 0.020 |
Why?
|
| Software Validation | 1 | 2005 | 8 | 0.020 |
Why?
|
| Quipazine | 1 | 1984 | 1 | 0.020 |
Why?
|
| Prolactin | 1 | 1984 | 44 | 0.020 |
Why?
|
| Quinolines | 1 | 1984 | 35 | 0.020 |
Why?
|
| Norepinephrine | 1 | 1984 | 79 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 1984 | 122 | 0.020 |
Why?
|
| Dopamine | 1 | 1984 | 86 | 0.020 |
Why?
|
| Pargyline | 1 | 1982 | 2 | 0.010 |
Why?
|
| 5-Hydroxytryptophan | 1 | 1982 | 3 | 0.010 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1982 | 11 | 0.010 |
Why?
|
| Hydrazines | 1 | 1982 | 11 | 0.010 |
Why?
|
| Isotopes | 1 | 2002 | 4 | 0.010 |
Why?
|
| Software | 1 | 2005 | 324 | 0.010 |
Why?
|
| United States | 1 | 2014 | 6282 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 969 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 2002 | 46 | 0.010 |
Why?
|
| Receptor, Nerve Growth Factor | 1 | 2002 | 2 | 0.010 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2002 | 6 | 0.010 |
Why?
|
| Calpain | 1 | 2002 | 8 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 1982 | 104 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2002 | 23 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2002 | 22 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 2001 | 14 | 0.010 |
Why?
|
| Neocortex | 1 | 2001 | 13 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2002 | 36 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 58 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2001 | 30 | 0.010 |
Why?
|
| Contig Mapping | 1 | 2001 | 4 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2001 | 19 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2002 | 358 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2002 | 162 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 1335 | 0.010 |
Why?
|
| Reference Values | 1 | 2001 | 316 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2002 | 210 | 0.010 |
Why?
|
| Milk Proteins | 1 | 2000 | 37 | 0.010 |
Why?
|
| Mitochondria | 1 | 2002 | 291 | 0.010 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 1998 | 7 | 0.010 |
Why?
|
| Karyotyping | 1 | 1998 | 42 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1998 | 82 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 579 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 1818 | 0.010 |
Why?
|
| Transgenes | 1 | 1998 | 149 | 0.010 |
Why?
|
| Mammary Glands, Animal | 1 | 1998 | 79 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 1995 | 5 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 1995 | 10 | 0.010 |
Why?
|
| Receptors, Somatomedin | 1 | 1996 | 10 | 0.010 |
Why?
|
| Genes, Lethal | 1 | 1996 | 39 | 0.010 |
Why?
|
| Gelatin | 1 | 1995 | 26 | 0.010 |
Why?
|
| Homozygote | 1 | 1996 | 115 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 1996 | 214 | 0.010 |
Why?
|
| Factor VIII | 1 | 1993 | 30 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 1993 | 18 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1993 | 56 | 0.010 |
Why?
|
| Fibroblast Growth Factor 4 | 1 | 1993 | 7 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1993 | 67 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1993 | 29 | 0.010 |
Why?
|
| Collagen | 1 | 1993 | 118 | 0.010 |
Why?
|
| NM23 Nucleoside Diphosphate Kinases | 1 | 1993 | 3 | 0.010 |
Why?
|
| Pepsin A | 1 | 1993 | 7 | 0.010 |
Why?
|
| Cathepsin D | 1 | 1993 | 10 | 0.010 |
Why?
|
| Collagenases | 1 | 1993 | 12 | 0.010 |
Why?
|
| Receptors, Laminin | 1 | 1993 | 17 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1993 | 78 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 1993 | 46 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1993 | 145 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1993 | 123 | 0.010 |
Why?
|
| Thymus Gland | 1 | 1993 | 219 | 0.010 |
Why?
|
| Spleen | 1 | 1993 | 483 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1993 | 421 | 0.010 |
Why?
|
| Estradiol | 1 | 1993 | 258 | 0.010 |
Why?
|
| Butorphanol | 1 | 1990 | 4 | 0.010 |
Why?
|
| Lidocaine | 1 | 1990 | 24 | 0.010 |
Why?
|
| Receptors, Opioid, mu | 1 | 1990 | 14 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 1993 | 264 | 0.010 |
Why?
|
| Preanesthetic Medication | 1 | 1990 | 2 | 0.010 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1990 | 26 | 0.010 |
Why?
|
| Computers | 1 | 1990 | 40 | 0.010 |
Why?
|
| Ketones | 1 | 1990 | 4 | 0.010 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 1990 | 18 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1990 | 155 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1990 | 132 | 0.010 |
Why?
|
| Pharmaceutical Vehicles | 1 | 1989 | 4 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1989 | 65 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1989 | 24 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 1989 | 53 | 0.010 |
Why?
|
| Veins | 1 | 1989 | 57 | 0.010 |
Why?
|
| Random Allocation | 1 | 1989 | 198 | 0.010 |
Why?
|
| Kinetics | 1 | 1990 | 710 | 0.010 |
Why?
|
| Methyltyrosines | 1 | 1984 | 2 | 0.000 |
Why?
|
| alpha-Methyltyrosine | 1 | 1984 | 2 | 0.000 |
Why?
|
| Caudate Nucleus | 1 | 1984 | 24 | 0.000 |
Why?
|
| Nucleus Accumbens | 1 | 1984 | 32 | 0.000 |
Why?
|
| Hypothalamus | 1 | 1984 | 123 | 0.000 |
Why?
|
| Potassium | 1 | 1984 | 96 | 0.000 |
Why?
|